Holen Sie sich die Stockscreener-App
0.5117
4.37%
-0.0234
Handel nachbörslich:
.52
0.0083
+1.62%
Schlusskurs vom Vortag:
$0.5351
Offen:
$0.543
24-Stunden-Volumen:
420.25K
Relative Volume:
0.51
Marktkapitalisierung:
$28.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.23M
KGV:
-0.9108
EPS:
-0.5618
Netto-Cashflow:
$-13.97M
1W Leistung:
-8.46%
1M Leistung:
-26.18%
6M Leistung:
-71.73%
1J Leistung:
-60.02%
1-Tages-Spanne:
$0.5019
$0.543
1-Wochen-Bereich:
$0.5019
$0.619
52-Wochen-Spanne:
$0.5019
$4.00
Heartbeam Inc Stock (BEAT) Company Profile
Firmenname
Heartbeam Inc
Sektor
Branche
Telefon
408-899-4443
Adresse
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT vs VEEV, BTSG, HQY, TEM, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
0.5117 | 28.40M | 0 | -20.23M | -13.97M | -0.5618 |
VEEV
Veeva Systems Inc
|
186.24 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
72.91 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
94.64 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
42.69 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
46.27 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2026-03-31 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-27 | Eingeleitet | D. Boral Capital | Buy |
| 2026-03-16 | Herabstufung | The Benchmark Company | Buy → Speculative Buy |
| 2025-12-11 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2025-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-31 | Eingeleitet | Roth Capital | Buy |
| 2020-09-11 | Eingeleitet | Needham | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-04-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-07-26 | Bestätigt | Lake Street | Buy |
| 2018-04-26 | Bestätigt | The Benchmark Company | Buy |
| 2018-02-23 | Bestätigt | Dougherty & Company | Buy |
| 2017-11-08 | Bestätigt | Dougherty & Company | Buy |
| 2017-10-26 | Eingeleitet | Raymond James | Outperform |
| 2017-10-24 | Eingeleitet | SunTrust | Buy |
| 2017-08-09 | Bestätigt | Dougherty & Company | Buy |
| 2017-07-19 | Bestätigt | The Benchmark Company | Buy |
| 2017-04-11 | Bestätigt | Dougherty & Company | Buy |
| 2016-12-02 | Eingeleitet | Dougherty & Company | Buy |
| 2016-09-13 | Eingeleitet | Sidoti | Buy |
| 2016-08-03 | Bestätigt | The Benchmark Company | Buy |
| 2015-07-28 | Bestätigt | Dougherty & Company | Buy |
| 2013-10-24 | Eingeleitet | The Benchmark Company | Buy |
| 2013-08-21 | Eingeleitet | Dougherty & Company | Buy |
Alle ansehen
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
TradingKey - TradingKey
Form 4 Heartbeam Inc For: 25 July By Investing.com - Investing.com South Africa
HeartBeam (NASDAQ: BEAT) CTO receives 105,740 shares in bonus grant - Stock Titan
HeartBeam, Inc. (BEAT) awards 167,760 RSUs to CFO as 2025 bonus - Stock Titan
HeartBeam, Inc. (BEAT) Grants 2,800,000 PRSUs and RSUs to President - Stock Titan
Heartbeam, Inc. (BEAT) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
Heartbeam, Inc. (BEAT) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Heartbeam, Inc. (BEAT) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Heartbeam, Inc. (BEAT) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now - The Globe and Mail
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
BEAT Initiated Coverage by Maxim Group -- Price Target Announced at $2.00 - GuruFocus
HeartBeam receives patent for multi-modal cardiac sensing device - Investing.com UK
HeartBeam receives patent for multi-modal cardiac sensing device By Investing.com - Investing.com Nigeria
HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device - Business Wire
Heartbeam Inc. (BEAT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Heartbeam Inc. Warrant (BEATW) Surges 16.61% as Penny Stock Tests Key LevelEarnings Sentiment - dars.gov.et
HeartBeam (BEAT) upgraded to buy: Here's what you should know - MSN
HeartBeam Receives Nasdaq Notice on Minimum Bid Price - TipRanks
HeartBeam Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns HeartBeam (NASDAQ: BEAT) over $1 minimum bid price rule - Stock Titan
Heartbeam, Inc. Warrant 2021-31.10.26 on HeartBeam Financial Disclosures & SEC Filings - TradingView
Heartbeam Inc. Warrant (BEATW) Edges Higher at $0.03 Amid Narrow Trading RangeDynamic Hedging - dars.gov.et
Heartbeam Inc. (BEAT) Dips 2.8% as Shares Test Near Support LevelsProfitability Factor - dars.gov.et
HeartBeam (BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital - Yahoo Finance
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule - Business Wire
HeartBeam (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital - TradingView
Heartbeam Inc. (BEAT) Q1 2026 Earnings: EPS Beat on Narrower Loss, Pre-Revenue Stage RemainsConsensus Miss Rate - dars.gov.et
HeartBeam (BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study - NewMediaWire
HeartBeam (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study - USA Today
HeartBeam (BEAT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BEAT - MarketBeat
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study - marketscreener.com
HeartBeam completes enrollment in heart attack detection study - Investing.com
Heartbeam Inc. (BEAT) Q1 2026 Earnings: EPS Surprise Beats Estimates, Stock Declines on Lack of Revenue DetailsProfit Warning Alert - dars.gov.et
HeartBeam (BEAT) Completes Enrollment in Heart Attack Detection Study Ahead of Schedule - GuruFocus
HeartBeam completes enrollment in heart attack detection study By Investing.com - Investing.com Nigeria
Heartbeam Inc. (BEAT) Slips 3.8% as Shares Test Key Support LevelsBeta Neutral Pair - dars.gov.et
Certain Restricted Stock Units of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026. - marketscreener.com
Certain Warrants of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026. - marketscreener.com
BEATW Warrants Hold at $0.03: Stalemate Persists for Heartbeam Inc. WarrantsInvestment Factor - dars.gov.et
HeartBeam (BEAT) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Slower Ramp - Yahoo Finance
Price to book forward of Heartbeam, Inc. – NASDAQ:BEAT - TradingView
Enterprise value to revenue forward of Heartbeam, Inc. – NASDAQ:BEAT - TradingView
Price to sales forward of Heartbeam, Inc. – NASDAQ:BEAT - TradingView
HeartBeam (BEAT) Reorganizes to Accelerate Global Commercialization Strategy - NewMediaWire
HeartBeam Reorganizes to Accelerate Global Commercialization of Cardiac Monitoring Technology - MEXC
HeartBeam (NASDAQ: BEAT) Reorganizes to Accelerate Global Commercialization Strategy - TradingView
HeartBeam, Inc. Actuals & Estimates (NASDAQ:BEAT) - TradingView
BEAT Forecast — Price Target — Prediction for 2027 - TradingView
HeartBeam CEO Robert Eno to Step Down; Founder Branislav Vajdic to Lead Operations - Moomoo
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition - 01net
Finanzdaten der Heartbeam Inc-Aktie (BEAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Heartbeam Inc-Aktie (BEAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Elfrink Willem | Director |
Apr 16 '26 |
Buy |
0.80 |
187,500 |
150,000 |
538,667 |
| JAFF MICHAEL R | Director |
Apr 16 '26 |
Buy |
0.80 |
31,250 |
25,000 |
31,250 |
| Vajdic Branislav | Director |
Apr 16 '26 |
Buy |
0.80 |
31,250 |
25,000 |
909,914 |
| Ferrari Richard | Director |
Apr 16 '26 |
Buy |
0.80 |
62,500 |
50,000 |
291,636 |
| ENO Robert Paul | President |
Apr 16 '26 |
Buy |
0.80 |
12,500 |
10,000 |
36,742 |
| Ortigas-Wedekind Marga | Director |
Apr 16 '26 |
Buy |
0.80 |
25,000 |
20,000 |
137,293 |
| STROME MARK E | Director |
Apr 16 '26 |
Buy |
0.80 |
750,000 |
600,000 |
3,650,000 |
| STROME MARK E | 10% Owner |
Dec 17 '25 |
Sale |
3.58 |
250,000 |
895,000 |
2,900,000 |
| de Urioste George | Director |
Dec 18 '25 |
Sale |
2.83 |
33,185 |
93,914 |
0 |
| de Urioste George | Director |
Dec 17 '25 |
Sale |
3.68 |
23,961 |
88,176 |
33,185 |
1.99%
2.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):